https://www.selleckchem.com/pr....oducts/gsk484-hcl.ht
Proteomics have already provided novel insights into the pathophysiology of heart failure (HF) with reduced ejection fraction. Previous studies have evaluated cross-sectional protein signatures of HF, but few have characterized proteomic changes following HF with reduced ejection fraction treatment with ARNI (angiotensin receptor/neprilysin inhibitor) therapy or left ventricular assist devices. In this retrospective omics study, we performed targeted proteomics (N=625) of whole blood sera from patients with American College of Cardio
Like
Comment
Share
